The treat-to-target paradigm: A cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients

Acta Clinica Belgica

Volumn 60, Issue 2, 2005, Pages 79-85

  Buysschaert, M ^a   Hermans, M P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Blood pressure; Glycaemic control; Lipids; Treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BELGIUM; BLOOD PRESSURE REGULATION; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; COHORT ANALYSIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HYPERTENSION; METABOLIC DISORDER; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PROGNOSIS; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; METABOLIC DISEASES; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 24044451526     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2005.015     Document Type: Article

References (42)

1. Buysschaert M, Vandenbroucke C, Barsoum S. A type 2 diabetes screening program by general practioners is a Belgian at risk population. Diabetes Metab 2001; 27: 109-114.
2. Zimmet P, Shaw J, Alberti KGMM. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetic Med 2003; 20: 693-702.
3. Haffner S, Lehto S, Ronneman T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
4. Haffner S. The importance of hyperglycaemia in the nonfasting state to the development of cardiovascular disease. Endocrine Reviews 1998; 19(5): 583-92.
5. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-57.
6. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. Br Med J 1998; 317: 703-13.
8. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5936 people with diabetes: a randomised placebo-controlled trial. Lancet 2002; 361: 2005-16.
9. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
10. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999; 42: 678-87.
11. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III), (comprend notamment les critères de définition du syndrome métabolique) Rapport complet disponible sur le site : http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. JAMA 2001; 285: 2486-97.
12. Hermans MP, Buysschaert M. Prévalence et caractéristiques cliniques de sujets diabétiques de type 2 en fonction de la présence d'un syndrome métabolique selon les critères ATP III. Diabetes Metab 2004; 30: 1S59, Abstract P104.
13. The Expert Committee on the diagnosis and complications of diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diab Care 1997; 20: 1183-97.
14. Buysschaert M, Dramais AS, Wallemacq P, Hermans MP. Hyper- homocysteinaemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy and insulin resistance. Diab Care 2000; 23: 1816-22.
15. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003; 89: 2560-72.
16. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertension 2003; 21: 1983-92.
17. American Diabetes Association. Standards of medical care in diabetes. Diab Care 2004; 27(Suppl 1): S15-S35.
18. Buysschaert M, Hermans MP. Non pharmacological management of type 2 diabetes. Acta Clin Belg 2004; 59: 14-19.
19. Slama G. Pourquoi faut-il tendre vers une polychimiothérapie systématique précoce chez les diabétiques de type 2. In : Journées Annuelles de Diabétologie, Hôtel-Dieu, Paris, Flammarion Médcine Sciences, 2001; 214-228.
20. Buysschaert M, Hermans MP. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes. Acta Clin Belg 1999; 54: 328-33.
21. Hermans MP, Buysschaert M, Dumont C. Clinical, biophysical and biochemical variables from African-heritage subjects with type 2 diabetes. Acta Clin Belg 2002; 57: 134-41.
22. Turner R, Cull L, Frighi U, Holman R for the United Kingdom Prospective Study (UKPDS) Group. Glycaemic control wit hdiet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirements for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
23. Buysschaert M, Lambert L, Donckier J, Jamart J. Etude d'un groupe de diabétiques inscrits dans la Convention INAMI autosurveillance glycémique. Acta Clin Belg 1993; 48: 316-23.
24. Haubursin Ch, Buysschaert M. Apports nutritionnels de patients diabétiques de type 1 et 2 belges. Acta Clin Belg 2001; 56: 91-95.
25. European Diabetes Policy Group : a desktop guide to type 2 diabetes mellitus. Diabetic Med 1999; 16: 716-30.
26. American Diabetes Association : Implications of the United Kingdom Prospective Diabetes Study (Position Statement). 2002; 25: S28-S32.
27. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45: S23-S28.
28. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diab Care 2001; 24: 758-767.
29. Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diab Care 2000; 23: 1130-6.
30. Hermans MP, Buysschaert M. Pharmacological treatment of type 2 diabetes. Acta Clin Belg 2004; 59: 59-66.
31. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease and atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
32. Cannon CP, Braunwald E, McCabe C et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
33. Sacks FM. Clinical usefulness of HDL cholesterol as a target to lower risk of coronary heart disease. Summary of evidence and recommendations of an expert group. Br J Cardiol 2003; 10: 297-304.
34. Scheen A, Van Gaal L, au nom des membres du groupe OCAPI. Risque cardiovasculaire absolu et objectifs thérapeutiques chez les patients diabétiques de type 2 : étude multicentrique belge OCAPI. Diabetes Metab, 2002; 28: S26, 049.
35. Scheen A, Van Gaal L. Poor achievement of NCEP III lipid targets in type 2 diabetic patients: the Belgian OCAPI Study. Diabetes, 2002; Suppl. 2: A496-497.
36. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus : results of the Hope Study and Micro-Hope Substudy. Lancet 2000; 355: 253-59.
37. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-53.
38. Neal B, Mac Mahon S, Chapman N. Effect of ACE-inhibitors, calcium antagonists and other blood-pressure lowering drugs : results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-64.
39. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
40. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-69.
41. Parving HH, Lehnert H, Bröchnner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
42. Barnett A, Bain S, Bouter P et al. for the Diabetics Exposed to Telmisartan and Enalopril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.